NORTHWEST BIOTHERAPEUTICS INC (NWBO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US66737P6007
NORTHWEST BIOTHERAPEUTICS INC financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 1.38 m USD |
| Operating income | -59.91 m USD |
| EBIT | -52.00 m USD |
| Net income | -60.16 m USD |
| Diluted EPS – continuing operations | -0.04 USD |
Full history since 2000, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About NORTHWEST BIOTHERAPEUTICS INC
Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addition, the company develops DCVax-Direct in Phase I trials to treat inoperable solid tumors. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
More stocks
- Virginia National Bankshares Corp (VABK)
- Sanara MedTech Inc. (SMTI)
- Shanghai Shibei Hi-Tech Co Ltd B (900902.SS)
- Zhejiang Benli Technology Co. Ltd. (301065.SZ)
- Pentapro Materials Inc. (7887.TWO)
- Shanghai Kaytune Industrial Co.Ltd (301001.SZ)
- Hangzhou SDIC Microelectronics Inc. A (688130.SS)
- Bangyan Technology Co. Ltd. A (688132.SS)
- Everyday Network (300295.SZ)
- Beijing Jiaoda Signal Technology (300851.SZ)
- Ever Ohms Technology Co. Ltd. (6834.TW)
- Real Consulting IT Business Solutions S.A. (REALCONS.AT)
Not investment advice. All data without warranty, price as of 02.11.2026. Details in the risk notice.